AU2011249789B2 - Dosage regimen of diaryl sulfide derivatives - Google Patents

Dosage regimen of diaryl sulfide derivatives Download PDF

Info

Publication number
AU2011249789B2
AU2011249789B2 AU2011249789A AU2011249789A AU2011249789B2 AU 2011249789 B2 AU2011249789 B2 AU 2011249789B2 AU 2011249789 A AU2011249789 A AU 2011249789A AU 2011249789 A AU2011249789 A AU 2011249789A AU 2011249789 B2 AU2011249789 B2 AU 2011249789B2
Authority
AU
Australia
Prior art keywords
dosage
compound
treatment
standard daily
daily dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2011249789A
Other languages
English (en)
Other versions
AU2011249789A1 (en
Inventor
Peter Gergely
Eric Legangneux
Erik Wallstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011249789A1 publication Critical patent/AU2011249789A1/en
Application granted granted Critical
Publication of AU2011249789B2 publication Critical patent/AU2011249789B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2011249789A 2010-05-06 2011-05-05 Dosage regimen of diaryl sulfide derivatives Expired - Fee Related AU2011249789B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10162082.1 2010-05-06
EP10162082 2010-05-06
PCT/EP2011/057210 WO2011138398A1 (en) 2010-05-06 2011-05-05 Dosage regimen of diaryl sulfide derivatives

Publications (2)

Publication Number Publication Date
AU2011249789A1 AU2011249789A1 (en) 2012-12-13
AU2011249789B2 true AU2011249789B2 (en) 2015-03-19

Family

ID=42236590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011249789A Expired - Fee Related AU2011249789B2 (en) 2010-05-06 2011-05-05 Dosage regimen of diaryl sulfide derivatives

Country Status (12)

Country Link
US (4) US20130210924A1 (enExample)
EP (1) EP2566473B1 (enExample)
JP (3) JP2013525469A (enExample)
KR (1) KR20130098885A (enExample)
CN (2) CN102917698A (enExample)
AU (1) AU2011249789B2 (enExample)
BR (1) BR112012028248A2 (enExample)
CA (1) CA2794607A1 (enExample)
EA (1) EA201201515A1 (enExample)
ES (1) ES2562416T3 (enExample)
MX (1) MX2012012925A (enExample)
WO (1) WO2011138398A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
LT2958624T (lt) * 2013-02-20 2021-08-10 Priothera Limited Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431284A1 (en) * 2001-09-27 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
EP1548003A1 (en) * 2002-09-19 2005-06-29 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
WO2009115954A1 (en) * 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
WO2004074297A1 (ja) 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
US20090275553A1 (en) * 2004-11-29 2009-11-05 Kovarik John M Dosage regimen of an s1p receptor agonist
EP2328571B1 (en) * 2008-08-18 2014-06-18 Novartis AG Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
SI3409274T1 (sl) * 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
BRPI0923213A2 (pt) * 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431284A1 (en) * 2001-09-27 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
EP1548003A1 (en) * 2002-09-19 2005-06-29 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
WO2009115954A1 (en) * 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OPPENHEIMER F. ET AL., TRANSPLANTATION, vol. 83, no. 5, 2007, pages 645-648 *
SHIMIZU H. ET AL., CIRCULATION, vol. 111, no. 2, 2005, pages 222-229. *

Also Published As

Publication number Publication date
JP6615247B2 (ja) 2019-12-04
AU2011249789A1 (en) 2012-12-13
JP2013525469A (ja) 2013-06-20
MX2012012925A (es) 2012-12-17
CA2794607A1 (en) 2011-11-10
JP6290963B2 (ja) 2018-03-07
JP2016183159A (ja) 2016-10-20
ES2562416T3 (es) 2016-03-04
CN102917698A (zh) 2013-02-06
BR112012028248A2 (pt) 2016-08-02
JP2018100280A (ja) 2018-06-28
US20130210924A1 (en) 2013-08-15
EA201201515A1 (ru) 2013-08-30
US20180161290A1 (en) 2018-06-14
WO2011138398A1 (en) 2011-11-10
EP2566473B1 (en) 2016-01-06
EP2566473A1 (en) 2013-03-13
CN106309416A (zh) 2017-01-11
US20140336265A1 (en) 2014-11-13
KR20130098885A (ko) 2013-09-05
US20170119702A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US20140148415A1 (en) Dosage regimen for a s1p receptor agonist
AU2010224355B2 (en) Treatment of autoimmune diseases
RU2010118457A (ru) Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (sip)
IL294658A (en) Dosage regimen of an s1p receptor agonist
EP1986623A2 (en) Method for treatment of neuropathic pain
JP2010537999A (ja) 麻酔薬節約効果を得るためのｎｍｄａ拮抗薬を用いる組成物および方法
US20180161290A1 (en) Dosage Regimen of Diaryl Sulfide Derivatives
MXPA05010763A (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8, 9-dioxo-2, 6-diazabiciclo [5.2.0] non-1(7) -en-2-il) alquil- fosfonico] y metodos de uso del mismo.
US20100093745A1 (en) Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
JP2013518894A (ja) ５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト
EP2566470A1 (en) Treatment of autoimmune diseases
RU2021123106A (ru) Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (s1p)
HK1150196A (en) Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee